Table 3.

Duration of incident cervical HPV-16, 18, 31, 33, 35, 45, 52, 58, and 59 infection episodes

Health state perspectiveNatural history perspective
Mean* duration, mo (95% CI)Median duration, mo (95% CI)Mean duration, mo (95% CI)Median duration, mo (95% CI)
HPV-16 (n = 273)15.5 (14.2-16.8)12.8 (11.9-15.1)20.2 (18.4-22.0)17.1 (15.1-20.2)
HPV-18 (n = 113)12.5 (11.0-14.0)9.6 (8.9-12.1)16.1 (13.9-18.2)12.4 (11.0-17.7)
HPV-31 (n = 157)14.2 (12.6-15.7)11.2 (10.3-12.6)18.2 (16.1-20.2)16.8 (14.1-20.3)
HPV-33 (n = 57)15.0 (12.5-17.5)13.8 (11.0-16.3)17.6 (14.4-20.7)14.9 (11.2-18.1)
HPV-35 (n = 52)12.6 (10.2-15.0)9.6 (7.1-14.5)13.8 (11.6-16.0)12.8 (8.4-20.2)
HPV-45 (n = 77)13.3 (11.1-15.5)10.7 (9.8-13.7)15.4 (13.0-17.8)12.2 (11.1-17.2)
HPV-52 (n = 173)14.8 (13.3-16.3)12.6 (10.9-16.2)17.2 (15.7-18.7)17.7 (14.9-21.5)
HPV-58 (n = 109)16.3 (13.6-19.0)12.6 (11.4-16.9)20.0 (16.7-22.5)15.9 (13.5-22.2)
HPV-59 (n = 172)12.1 (10.9-13.3)10.6 (8.9-11.9)13.0 (11.8-14.3)11.7 (10.0-12.5)
  • *Because individual observations with the longest follow-up times were censored in analyses for HPV-16, 18, 31, 35, and 52, mean durations of infections are slightly underestimated.

  • Because individual observations with the longest follow-up times were censored in analyses of HPV-16, 18, 35, 52, and 59, mean durations of infections are slightly underestimated.